ArticleScientific reports2025
A simulation-based plasmonic terahertz nanosensor with graphene-enhanced sensitivity for diabetes monitoring.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a dual-mode terahertz plasmonic nanosensor based on a novel graphene-SiO₂-gold multilayer architecture, engineered for rapid and highly sensitive non-invasive detection of blood glucose concentration via refractive index sensing. This is the first sensor that simultaneously achieves two sharp, independently tunable resonant modes at 2.48-2.50 THz (mode one) and 6.01-6.12 THz (mode two) through the synergistic interaction of localized surface plasmon resonance (LSPR) and near-perfect impedance matching. The second mode exhibits an outstanding sensitivity of 4.5 THz /RIU and a figure of merit (FoM) of 40.9 among the highest reported in terahertz glucose sensing along with a limit of detection (LOD) of 6 × 10⁻³ RIU across the physiologically relevant refractive index range (n = 1.33-1.378). The dual-mode operation offers inherent self-referencing capability against environmental variations, while the validated equivalent circuit model provides deep physical insight and design flexibility. Compared with previously reported terahertz and metamaterial sensors, the proposed device achieves a superior combination of sensitivity, FoM, linearity, and robustness, indicating strong potential for integration into future wearable, real-time, non-invasive diabetes monitoring platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.